These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30252601)

  • 1. Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.
    Richter F; Zettlitz KA; Seifert O; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann RE
    MAbs; 2019 Jan; 11(1):166-177. PubMed ID: 30252601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.
    Zettlitz KA; Lorenz V; Landauer K; Münkel S; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann R
    MAbs; 2010; 2(6):639-47. PubMed ID: 20935477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.
    Richter F; Seifert O; Herrmann A; Pfizenmaier K; Kontermann RE
    MAbs; 2019; 11(4):653-665. PubMed ID: 30929560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
    Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
    Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.
    Richter F; Liebig T; Guenzi E; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann RE
    PLoS One; 2013; 8(8):e72156. PubMed ID: 23977237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
    J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.
    Goodall LJ; Ovecka M; Rycroft D; Friel SL; Sanderson A; Mistry P; Davies ML; Stoop AA
    PLoS One; 2015; 10(9):e0137065. PubMed ID: 26352810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
    Inoue M; Tsuji Y; Yoshimine C; Enomoto S; Morita Y; Osaki N; Kunishige M; Miki M; Amano S; Yamashita K; Kamada H; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2020 Jul; 295(28):9379-9391. PubMed ID: 32398258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.
    Dong Y; Fischer R; Naudé PJ; Maier O; Nyakas C; Duffey M; Van der Zee EA; Dekens D; Douwenga W; Herrmann A; Guenzi E; Kontermann RE; Pfizenmaier K; Eisel UL
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12304-12309. PubMed ID: 27791020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis.
    Williams SK; Fairless R; Maier O; Liermann PC; Pichi K; Fischer R; Eisel ULM; Kontermann R; Herrmann A; Weksler B; Romero N; Couraud PO; Pfizenmaier K; Diem R
    Sci Rep; 2018 Sep; 8(1):13628. PubMed ID: 30206422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.
    Steeland S; Puimège L; Vandenbroucke RE; Van Hauwermeiren F; Haustraete J; Devoogdt N; Hulpiau P; Leroux-Roels G; Laukens D; Meuleman P; De Vos M; Libert C
    J Biol Chem; 2015 Feb; 290(7):4022-37. PubMed ID: 25538244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.
    Inoue M; Ando D; Kamada H; Taki S; Niiyama M; Mukai Y; Tadokoro T; Maenaka K; Nakayama T; Kado Y; Inoue T; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2017 Apr; 292(16):6438-6451. PubMed ID: 28235800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss.
    Espirito Santo AI; Ersek A; Freidin A; Feldmann M; Stoop AA; Horwood NJ
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1145-1150. PubMed ID: 26208457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis.
    Fiedler T; Fairless R; Pichi K; Fischer R; Richter F; Kontermann RE; Pfizenmaier K; Diem R; Williams SK
    J Neuroinflammation; 2023 Apr; 20(1):100. PubMed ID: 37122019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
    Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation.
    Richter F; Williams SK; John K; Huber C; Vaslin C; Zanker H; Fairless R; Pichi K; Marhenke S; Vogel A; Dhaen MA; Herrmann S; Herrmann A; Pfizenmaier K; Bantel H; Diem R; Kontermann RE; Fischer R
    Front Immunol; 2021; 12():705485. PubMed ID: 34305946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.
    Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Minowa K; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Tsunoda S; Tsutsumi Y
    Pharmazie; 2010 Feb; 65(2):93-6. PubMed ID: 20225650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity.
    Moosmayer D; Dübel S; Brocks B; Watzka H; Hampp C; Scheurich P; Little M; Pfizenmaier K
    Ther Immunol; 1995 Feb; 2(1):31-40. PubMed ID: 7553069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.